Moleculin Biotech (NASDAQ:MBRX) is a dedicated biopharmaceutical company that focuses on the development of oncology drug candidates for the treatment of highly resistant tumors and viruses. Their research pipeline is rich with projects that aim to bring revolutionary treatments to patients worldwide, primarily focusing on leveraging small molecule drugs to target cancer cells and viral infections effectively. One of their noteworthy objectives is to advance the science of treating cancers that have proven difficult to combat with existing medications, striving to unlock new pathways to remission and improve patient outcomes. Through rigorous research, clinical trials, and strategic partnerships, Moleculin Biotech is committed to pushing the boundaries of medicine to provide new hope for patients facing cancer and other serious diseases.